NCT05531565
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentBiogen
~450 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:LitifilimabPlacebo
At a glance
Recruiting sites
0 of 315 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1
Measured over Week 16
+1 more outcome measured
Conditions
Where it's being run
315 sites across 136 statesPhilippines11
Poland11
Ukraine11
Florida9
Texas9
Bulgaria8
Italy8
Chile7
Study leadership
- Medical Director · STUDY_DIRECTOR · Biogen
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1Week 16
- Part B: Percentage of Participants who Achieve Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI-70) Response, Defined as ≥ 70% Decrease in CLASI-A Score From BaselineBaseline to Week 24